US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Eneco Refresh Limited (ERG) 銘柄情報

Eneco Refresh Limited (ERG)

0.015

0.00

(0.00%)

終了 6月16日 3:00PM

Eneco Refresh Limited (ERG) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.015

( - )

買値

0.015

売値

0.018

出来高

0.00

0.00 日の範囲 0.00

0.011 52 週間の範囲 0.024

時価総額

前日終値

0.015

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 193,845

発行済株式数

272,358,347

配当利回り

PER

14.22

1 株当たり利益 (EPS)

-

歳入

17.15M

純利益

276.46k

Eneco Refresh Limited produces and distributes bottled water and accessories and filtration systems in Australia. It operates through the Refresh Water and Refresh Plastics segments. The company offers a range of plastic bottles, containers, and jars for the beer, wine, and beverage industries; wate... Eneco Refresh Limited produces and distributes bottled water and accessories and filtration systems in Australia. It operates through the Refresh Water and Refresh Plastics segments. The company offers a range of plastic bottles, containers, and jars for the beer, wine, and beverage industries; water tanks, caravan tanks, jerrycans, watering cans, and vehicle parts; and Ampi activity toys. It also engages in the rental of water coolers; production of distilled drinking water; supply of point-of-use water purifiers on monthly rental; contract manufacturing of custom molded products; and distribution of polyethylene terephthalate kegs. In addition, the company provides a range of water purifiers, including sediment and carbon filters, reverse osmosis, distillers, and air-to-water generators. Further, it offers honey under the JAS Honey brand. The company was formerly known as Refresh Group Limited. Eneco Refresh Limited was incorporated in 1997 and is headquartered in Malaga, Australia. Eneco Refresh Limited operates as a subsidiary of Eneco Investment Pte Ltd. 詳細を表示

セクター

Consumer Staples

業界

Beverages - Non-alcoholic

ウェブサイト

www.eneco-refresh.com.au

本社

Malaga, Australia

設立

1997

Eneco Refresh Limited is listed in the Consumer Staples sector of the オーストラリア証券取引所 with ticker ERG. The last closing price for Eneco Refresh was AUD0.02. Over the last year, Eneco Refresh shares have traded in a share price range of AUD 0.011 to AUD 0.024.

Eneco Refresh currently has 272,358,347 shares in issue. The market capitalisation of Eneco Refresh is AUD4.09 million. Eneco Refresh has a price to earnings ratio (PE ratio) of 14.22.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0.015	0.015	0.013	319968	0.01481229	DE
12	-0.001	-6.25	0.016	0.024	0.012	193845	0.01623704	DE
26	0	0	0.015	0.024	0.012	176690	0.01642973	DE
52	0.002	15.3846153846	0.013	0.024	0.011	105617	0.01570293	DE
156	-0.002	-11.7647058824	0.017	0.025	0.007	146882	0.01455841	DE
260	-0.025	-62.5	0.04	0.046	0.007	119437	0.01737322	DE

ERG - Frequently Asked Questions (FAQ)

What is the current Eneco Refresh Limited share price?

The current share price of Eneco Refresh Limited is AUD 0.015

How many Eneco Refresh Limited shares are in issue?

Eneco Refresh Limited has 272,358,347 shares in issue

What is the market cap of Eneco Refresh Limited?

The market capitalisation of Eneco Refresh Limited is AUD 4.09M

What is the 1 year trading range for Eneco Refresh Limited share price?

Eneco Refresh Limited has traded in the range of AUD 0.011 to AUD 0.024 during the past year

What is the PE ratio of Eneco Refresh Limited?

The price to earnings ratio of Eneco Refresh Limited is 14.22

What is the cash to sales ratio of Eneco Refresh Limited?

The cash to sales ratio of Eneco Refresh Limited is 0.24

What is the registered address of Eneco Refresh Limited?

The registered address for Eneco Refresh Limited is 17 Denninup Way, Malaga, Western Australia, 6090

What is the Eneco Refresh Limited website address?

The website address for Eneco Refresh Limited is www.eneco-refresh.com.au

Which industry sector does Eneco Refresh Limited operate in?

Eneco Refresh Limited operates in the Beverages - Non-Alcoholic sector

price_and_volume

price_and_volume 3分前

Gonna have to bump the A/S then...
He said recently that they are looking at another acquisition...and he will dilute with shares to get it. Agreed - I posted the same, "where's the finance coming from for acquisitions?"...

Supposed 400MM shares going to $GTVH (believe it when

StockItOut

StockItOut 4分前

WKSP Weekly chart: https://schrts.co/IIIuZpgy

CelestialSage6

CelestialSage6 5分前

I understand that Halozyme has not signed any exclusive agreements regarding treatments or indications related to Dupixent, so why is Sanofi collaborating with Alteogen?

Also, Halozyme's mdase patent is being invalidated due to Merck. Alteogen's technology is more advanced than Halozy

Wolf-man jack

Wolf-man jack 6分前

WQLF SAYS: Have Mercy WQLF ahoooooo

Q: Why hasn't CV SCIENCES been accepted in the CMS Medicare Pilot Program?

Ai Generated:

CV Sciences has not been "accepted" into the CMS Medicare Pilot Program because the pilot is a provider-led incentive, not a pro

price_and_volume

price_and_volume 8分前

What reasonable expectation is there of PPS responding?
whether management can successfully execute on the vision they have laid out. Nobody cares about "the company" or "the management" or "their vision" or your two-bit-MBA-tutorials-in-a-post.

Enough of all that garbage.

mrwrn2010

mrwrn2010 10分前

Disagree. The outcome of OxyContin litigation was unknown 9 months to a year ago. You can guess at a variety of outcomes, sure, but it’s not certain. Same thing with human trials - we don’t have positive trial results for anything in the pipeline until we have them. What passes in vitro may not pass

PEACHMAN

PEACHMAN 12分前

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177680761

IFUS STRONG

price_and_volume

price_and_volume 13分前

I get that, but that's not what I asked.

I'm not bullying you or accusing you of pumping.

You repeatedly point out what you consider to be nefarious shenanigans, so I asked: PPS hasn't effectively changed in THREE YEARS , other than a few short days 1 year ago this wee

Homework.Investwell

Homework.Investwell 20分前

2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800

Suite 800 is empty....🤔

Linda lives in Missouri now but headquarters could be moved anywhere...or will they need it?

I think we're going to find out by the end of the sum

Mdk1

Why this paper is highly interesting for Lightwave Logic (GROK)
This is a top-scored paper that strongly validates Lightwave Logic’s Perkinamine™ chromophore series 3 as a leading electro-optic material for next-generation datacenter optics.

Key Reasons Why It Matters:

janice shell

janice shell 29分前

Now that's a real head-scratcher! But shorts have to be smart, so I'd say torso and head.

gitreal

gitreal 31分前

Anyone with half a Brian can see this company is being crazy shorted!

Which half? Torso and head?

HyGro

NWBO could file an FDA application anytime but they haven't and have shown no intent to do so. Instead they are just burning more shareholder cash and if approved, will lose money on every dose because NICE will hammer the reimbursement down below Advent's costs. NWBO will lose money and collaps

US Market News

US Market News 37分前

TotalEnergies SE: Disclosure of Transactions in Own SharesJune 16, 2026 2:00 AM
Business Wire Regulatory News In accordance with the authorizations given by the shareholders’ general meeting on May 29, 2026, to trade on its shares and pursuant to applicable law on share

HyGro

Sorry, not enough. NWBO won't make any profit selling in the UK. NICE hates personalized oncology treatments and won't pay enough for NWBO to make a profit.
That's what counts. And NWBO will go under or just become Advent Contract Manufacturer. They have no cash or credit to fund any sub

biotechinvestor1

biotechinvestor1 41分前

Don’t start spazzing again, Alteogen circus clown. The Sanofi news is old.
Once Merck settles/licenses from Halozyme, Sanofi and all others will follow.
Your Alteogen stole IP from Halozyme and will pay a price for it. You can count on it.
The companies who have signed with Alte

Steady_T

Steady_T 41分前

Your theory will be put to the test after UK approval. I give it 6 months as a guess.

HyGro

What's true is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How many years are you going to wait to find out???

HyGro

What's True is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How long are you going to wait to find out???

Mdk1

Google Scholar alert - new article: "A Comparison of Plasmonic Modulator Structures in the O- and C-Band for the 400G/Lane IM/DD Era"
>>> " In ALL cases, the same electro-optic organic material, Lightwave Logic’s PerkinamineTM
chromophore series 3, was used " !
https://ieeexplor

CelestialSage6

CelestialSage6 49分前

Stop talking nonsense. Sanofi is conducting clinical trials using Alteogen's technology; what are your thoughts on this? Did you sense a crisis for Halozyme?

biotechinvestor1

biotechinvestor1 51分前

I love it when Alteogen fanboys post on this board. Nearly every time they show up, Halozyme has a run up.

DR_rugby

DR_rugby 52分前

Prophecy is coming

https://www.cnbc.com/2026/06/16/boj-rate-hike-historic-inflation.html

Japanese rates are going higher

Yen is yet to be stabilize

The great unwinding is coming soon

GLTA

BigBadWolf

BigBadWolf 59分前

Authorized Shares 1,800,000,000 06/15/2026
Outstanding Shares 1,619,034,363 06/15/2026 >5m
Restricted 480,530,670 06/15/2026 >5m
Unrestricted 1,138,503,693 06/15/2026
Held at DTC 1,011,499,104 06/15/2026 >8m

Authorized Shares 1,800,000,000 06/05/2026

4retire

4retire 1時間前

One has to question why a “cash rich” company would need to raise $20-25 billion by going to bond sales that will be in 7 tranches, ranging from 2 to 30 years. The statement is that it’s for general purposes and to redo some current debt financing.

Based on recent financials, NVDA’

Bmo Strategic Fixed Inco...

GSRX Industries (EM)

Euronext G Orange 261021...

Neuberger Growth ETF

Euronext US Basic Materi...

Amundi Asset Management ...

Northwest Biotherapeutics (QB)

Callable Zero Coupon Not...

Nordic Waterproofing Hol...

POET Technologies

WisdomTree Commodity Sec...

SANTOS BRASIL ON

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。